Format

Send to

Choose Destination
Gynecol Oncol Rep. 2016 Dec 14;19:10-12. doi: 10.1016/j.gore.2016.12.003. eCollection 2017 Feb.

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1).

Author information

1
Department of Obstetrics & Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
2
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, United States.

Abstract

BACKGROUND:

The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed.

CASE:

We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC overexpressing HER2/neu at 3 + level by IHC treated with the anti-HER2/neu antibody-drug-conjugate (ADC) trastuzumab-emtansine (TDM-1-Kadcyla-Genentech/Roche). She experienced a remarkable clinical response to TDM-1 with a complete resolution of a large metastatic, radiation/chemotherapy resistant tumor deposit in her abdominal wall muscle confirmed by multiple CAT scans and a prolonged systemic control of her disease.

CONCLUSION:

TDM-1 may represent a novel treatment option for recurrent/metastatic HER2/neu-positive USC patients refractory to salvage-treatment.

KEYWORDS:

HER2/neu; Trastuzumab-emtansine; Uterine serous carcinoma

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center